Lupin receives warning letter from USFDA for Tarapur facility

Lupin Ltd has received a warning letter from the U.S. FDA for the Company's Tarapur, Maharashtra (India) facility. The U.S. FDA had inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022.

The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

We are committed to addressing the concerns raised by the U.S. FDA and will work with the U.S. FDA to resolve these issues at the earliest. We uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all our facilities.

Source : Equity Bulls

Keywords

Lupin WarningLetter USFDA Tarapur Maharashtra